1. Design and synthesis of 7-O-1,2,3-triazole hesperetin derivatives to relieve inflammation of acute liver injury in mice.
- Author
-
Zheng Y, Zhang YL, Li Z, Shi W, Ji YR, Guo YH, Huang C, Sun GP, and Li J
- Subjects
- Animals, Carbon Tetrachloride, Cell Survival drug effects, Cells, Cultured, Dose-Response Relationship, Drug, Hesperidin chemical synthesis, Hesperidin chemistry, Inflammation metabolism, Inflammation pathology, Liver injuries, Liver metabolism, Mice, Mice, Inbred C57BL, Molecular Structure, Nitric Oxide analysis, Nitric Oxide biosynthesis, RAW 264.7 Cells, Reactive Oxygen Species analysis, Reactive Oxygen Species metabolism, Structure-Activity Relationship, Triazoles chemical synthesis, Triazoles chemistry, Drug Design, Hesperidin pharmacology, Inflammation drug therapy, Liver drug effects, Triazoles pharmacology
- Abstract
Based on the previous research results of our research group, to further improve the anti-inflammatory activity of hesperetin, we substituted triazole at the 7-OH branch of hesperetin. We also evaluated the anti-inflammatory activity of 39 new hesperetin derivatives. All compounds showed inhibitory effects on nitric oxide (NO) and inflammatory factors in lipopolysaccharide-induced RAW264.7 cells. Compound d5 showed a strong inhibitory effect on NO (half maximal inhibitory concentration = 2.34 ± 0.7 μM) and tumor necrosis factor-α, interleukin (IL)-1β, and (IL-6). Structure-activity relationships indicate that 7-O-triazole is buried in a medium-sized hydrophobic cavity that binds to the receptor. Compound d5 can also reduce the reactive oxygen species production and significantly inhibit the expression of inducible NO synthase and cyclooxygenase-2 through the nuclear factor-κB signaling pathway. In vivo results indicate that d5 can reduce liver inflammation in mice with acute liver injury (ALI) induced by CCI
4 . In conclusion, d5 may be a candidate drug for treating inflammation associated with ALI., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2021 Elsevier Masson SAS. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF